Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH5 | Q6P6C2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3548659 | 0.80 | PLCG1 (0.34) | PLCG1HTTL3MBTL1MAPT | |
| SCHEMBL6701541 | 0.77 | POLB (0.32) | SMN1; SMN2POLBPLCG1RAB9AL3MBTL1 | |
| SCHEMBL3046825 | 0.77 | POLB (0.32) | SMN1; SMN2POLBPLCG1RAB9AL3MBTL1 | |
| SCHEMBL6268828 | 0.77 | POLB (0.32) | SMN1; SMN2POLBPLCG1RAB9AL3MBTL1 | |
| SCHEMBL6701542 | 0.77 | POLB (0.32) | SMN1; SMN2POLBPLCG1RAB9AL3MBTL1 | |
| SCHEMBL6702522 | 0.77 | PLCG1 (0.35) | SMN1; SMN2POLBPLCG1KMT2ARAB9A | |
| SCHEMBL3049029 | 0.77 | PLCG1 (0.35) | SMN1; SMN2POLBPLCG1KMT2ARAB9A | |
| SCHEMBL6702524 | 0.77 | PLCG1 (0.35) | SMN1; SMN2POLBPLCG1KMT2ARAB9A | |
| SCHEMBL679843 | 0.77 | PLCG1 (0.32) | SMN1; SMN2POLBPLCG1HTTL3MBTL1 | |
| SCHEMBL4794959 | 0.76 | POLB (0.37) | SMN1; SMN2POLBPLCG1HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | WYETH | 2004-04-22 | — | — | US | disclosed |
| US-20040053913-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053913-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | ALKBH5 951/4885SMN1; SMN2 1450/4885POLB 338/4885 |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | PGLS, BPGM, B2M | ALKBH5 1521/4885SMN1; SMN2 2073/4885POLB 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.